February 26, 2025

Perseus Proteomics Inc.

Securities Code: 4882 Growth TSE

To all stakeholders,

PPMX-T003: Selection as FY2026/3 Project Promoting Support for Drug Discovery Support Program for Orphan drug prior to the Designation by AMED

Perseus Proteomics Inc. ("the Company") is pleased to announce that the research and development of the Company on utilizing its pipeline drug candidate as treatment for aggressive NK cell leukemia ("ANKL") has been selected as Project Promoting Support for Drug Discovery Support Program for Orphan drug prior to the Designation by Japan Agency for Medical Research and Development (AMED).

1. Title of the project: "Development of Therapeutic Drug (PPMX-T003) for Aggressive NK Cell Leukemia"

2. Representative organization: Perseus Proteomics Inc.

3. Outline and purpose of the research

ANKL originates from NK (natural killer) cells, a type of immune cells. It is very rare, fulminant type of refractory hematological malignancy, where symptoms will progress rapidly once it appears. The research group of Dr. Ai Kotani at Osaka Metropolitan University has discovered that PPMX-T003 has the potential of a therapeutic drug for ANKL. Consequently, the research group and the Company have been actively engaged in its research and development. Following the selection as the same project by AMED in FY2023/3, a phase I/II clinical trial started with the sample size of 7 at Hiroshima University Hospital and other institutions.

The initial clinical trial was scheduled to end by the end of March 2025, however, the clinical trial coordinator assessed that completion by the date would be challenging and registered a 1-year extension of the trial period on jRCT. For the support for continuation and completion of the clinical trial, regulatory consulting with PMDA, and other measures, the Company applied for the program and was successfully selected for the program.

While this subsidy program is set to continue for three years from April 2025 to March 2028, the clinical study itself is planned to run until the end of March 2026. In FY2026/3, the Company anticipates a subsidy of 100 million yen which will be allocated towards the clinical trial expenses.

4. Future forecast

The Company will reflect the impact on this selection to the business results forecast for FY2026/3.

AMED website: program introduction

END